Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The primary material change reported is a movement in the GlaxoSmithKline US Retirement Savings Plan ("the Plan") on July 29, 2005. The number of Ordinary Share ADRs held by the fund increased from 18,317,801 to 18,374,700. This transaction occurred at an average price of $47.65 per share.
Management Commentary and Risks
The Plan is a discretionary fund where all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Two directors, Dr. J P Garnier and Dr. T Yamada, are noted as potentially interested in the shares held in the fund in the same manner as other employees. The filing contains no specific guidance, outlook, or discussion of operational risks beyond the standard disclosure requirements.
Key Facts for Investor Verification
- The increase in ADR holdings within the US Retirement Savings Plan was 56,899 shares.
- The transaction price averaged $47.65 per share.
- Directors Dr. J P Garnier and Dr. T Yamada have potential interests in the fund's holdings.
- The filing was signed by Victoria Llewellyn as the Authorised Signatory on August 2, 2005.